DOCSLIB.ORG

Product Listing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Listing The Difference is in the Results. Go Ahead. Test Us! Product Listing Immunoassays, Proteins, Antibodies, and Custom Manufacturing Services Biomedical Research Tools for • Reproductive Function • Growth Factors • Pregnancy Coming Soon: • Neuronal Disorders • BMP-15 • Cardiovascular Disease • BMP-15 / GDF-9 Heterodimer Complex • GDF-9 • Oncology • GLP-1 • GLP-2 • Glucagon Regulation • Glucagon • PAPP-A / Stanniocalcin 2 • Animal Specific Assays Complex • Research Reagents ° Monoclonal Antibodies ° Recombinant Proteins www.AnshLabs.com 1 Introduction At Ansh Labs, we understand the importance of your research and we pride ourselves on developing and manufacturing immunoassays and ISO 9001:2008 ISO 13485:2003 sharing our knowledge. We’re not just another manufacturer but a dedicated team working to turn hope for a healthier future into a reality. Our passion is helping you reach your goals. From our beginnings, Ansh Labs has remained committed to identifying and developing emerging biomarkers. Quality Policy Ansh Labs is dedicated to exceeding our customers’ expectations in terms of quality of the products and the services we provide. Ansh Labs follows guidelines of the US FDA Good Manufacturing Practice (cGMP) 21 CFR820, CMDR–Quality System, and the ISO 13485 and ISO 9001 International Standards. With this quality system, we have dedicated ourselves to a strategy of continuous improvement, constantly seeking to understand the expectations of our customers and striving to exceed those expectations at every juncture. It is the responsibility of Ansh Labs’ Senior Management to ensure through proper training that the Quality Policy is understood, implemented, and maintained at all levels within the organization. All Ansh Labs employees adhere to the spirit and letter of the Company’s Quality Policy, as well as the directives of the Quality Manual and its subordinate documents. Gopal Savjani President and CEO www.AnshLabs.com 2 Table of Contents Feature Sections Page Immunoassays (con't) Catalog # Page Product Focus - AMH 4 MBP ELISA AL-108 24 Product Focus - picoAMH 5 MBP CLIA AL-208 24 Product Focus - Animal Specific AMH Assays 6 Oxyntomodulin ELISA AL-139 25 Product Focus - Inhibin B 7 PAPP-A ELISA AL-106 20 Overview - Activins and Inhibins 8-9 PAPP-A CLIA AL-206 20 Overview - Growth Factors 10-11 picoPAPP-A ELISA AL-101 20 Educational Graphic - Folliculogenesis 12-13 picoPAPP-A CLIA AL-201 20 Animal Reactivity Matrix 14-15 PAPP-A, Mouse ELISA AL-158 20 PAPP-A2 ELISA AL-109 21 Stanniocalcin 2 ELISA AL-143 24 Immunoassays Catalog # Page Specialty Controls (Ansh Check) Catalog # Page Activin A ELISA AL-110 17 ü AMH Tri-Level Controls AL-CTR-401 16 Activin A CLIA AL-210 17 Inhibin B Controls AL-CTR-402 19 Activin B ELISA AL-150 17 Activin B, Mouse ELISA AL-156 18 Antibodies Catalog # Page AMH, Ultra-Sensitive ELISA AL-105 16 BMP-15 mAb AB-324-AB-### 27 AMH, Ultra-Sensitive CLIA AL-205 16 Follistatin mAb AB-307-AF-### 27 picoAMH ELISA AL-124 16 GDF-9 mAb AB-325-AG-### 27 AMH, Dried Blood Spot ELISA AL-129 16 IGF-I mAb AB-309-AI-### 28 AMH, Bovine ELISA AL-114 17 IGF-II mAb AB-312-AI-### 28 AMH, Canine ELISA AL-116 17 IGFBP-2 mAb AB-313-AI-### 28 AMH, Caprine ELISA AL-154 17 IGFBP-3 mAb AB-310-AI-### 28 AMH, Equine ELISA AL-115 17 IGFBP-4 mAb AB-308-AI-### 28 AMH, Ovine ELISA AL-155 17 IGFBP-5 mAb AB-311-AI-### 28 AMH, Porcine ELISA AL-169 17 Inhibin Alpha mAb AB-304-AI-### 27 AMH, Primate ELISA AL-105 17 Inhibin A mAb AB-305-AI-### 27 AMH, Rat and Mouse AL-113 17 Inhibin B mAb AB-306-AI-### 27 C-Peptide of Insulin ELISA AL-151 25 MBP mAb AB-314-AM-### 27 Follistatin ELISA AL-117 18 PAPP-A mAb AB-301-AP-### 27 Follistatin CLIA AL-217 18 PAPP-A2 mAb AB-302-AP-### 27 Follistatin-Like 3 ELISA AL-152 18 Vitamin D mAb AB-315-V-### 27 IGF-I, Total ELISA AL-121 21 IGF-I, Bioactive ELISA AL-122 21 Recombinant Proteins Catalog # Page IGF-I, Total Rat and Mouse ELISA AL-137 21 Recombinant Dimeric PAPP-A Ag AG-301-BP024 28 IGF-I, Free Rat and Mouse ELISA AL-136 22 Recombinant Human Inhibin A Ag AG-305-AI035 28 IGF-II ELISA AL-131 22 Recombinant Human Inhibin B Ag AG-306-BI043 28 IGFBP-2 ELISA AL-140 22 Recombinant PAPP-A2 Ag AG-302-BP033 28 IGFBP-3, Total ELISA AL-120 23 Biochemicals Catalog # Page IGFBP-3, Intact ELISA AL-149 23 AMH Stabilizing Buffer AA-006-1000 28 IGFBP-4, Total ELISA AL-126 23 AnshLite Substrate & Catalyst ALA-100A & ALB-100B 28 IGFBP-4, Intact ELISA AL-128 23 IGFBP-5 ELISA AL-127 24 Equipment Catalog # Page Inhibin A ELISA AL-123 19 AnshLite Luminometer AL-LB962 26 Inhibin A, Canine, Equine, Rodent ELISA AL-161 20 Inhibin B ELISA AL-107 19 Other Page Inhibin B CLIA AL-207 19 Bibliography 29-30 Inhibin B, Canine, Equine, Rodent ELISA AL-163 20 Terms and Conditions 31 Inhibin, Total ELISA AL-134 19 Index by Catalog Number 32 www.AnshLabs.com 3 Product Focus Anti-Müllerian Hormone* Ansh Labs Advantage Accurate Specific to human AMH (associated form) detects the full length and enhanced biologically active associated forms of human AMH Standardized Standardized recombinant human AMH calibrators recombinant ensure accuracy and reproducibility assay–to–assay and human AMH calibrators lot–to–lot Unique mAbs developed against specific linear epitopes on the associated dimers of AMH specificity and consistency of AMH detection Analytical measurable range of 0.08—14.2 ng/mL Specific wide dynamic range reduces repeat testing of samples Sensitive to ~23 pg/mL Specific to improved detection rate in research studies of the full length compromised gonadal function and cleaved complex forms AMH concentration in a sample does not appear to of AMH be impacted significantly by normal storage and transportation conditions if proper sample collection practices are adhered. AMH is a useful research tool in Reproductive Endocrinology studies Pepinski, R.B., et al. (1988) J. Biol. Chem., 263, 18961–18964. related to: • Primary ovarian insufficiency Reliable • Oncofertility • Gonadotoxicity Excellent precision • Menopause and consistency of • Premature ovarian aging performance from • PCOS – biochemical feature of polycystic ovary assay–to–assay, lot–to– lot and lab–to–lab syndrome • Neonatal gender determination • Cryptorchidism • Testicular (Leydig/Sertoli cell) function * Within the U.S., intended for Research Use Only (RUO). Not for use in diagnostic or therapeutic procedures. www.AnshLabs.com 4 Product Focus - picoAMH (Anti–Müllerian Hormone)* Ansh Labs Advantage Accurate Analytical measurable range of 3.8 - 1,091 pg/mL Serum samples were analytical sensitivity to ~2 pg/mL to distinguish declining pre-diluted 1:10 or 1:20 AMH levels; the only assay available to measure AMH in prior to assay in picoAMH ELISA (AL-124). Matched this range serum samples were run undiluted in Ultra- Sensitive AMH ELISA Specific to human AMH (AL-105). detects the full length and enhanced biologically active Passing-Bablok associated forms of human AMH regression: picoAMH ELISA = 0.92 US AMH ELISA – 50.66 Standardized recombinant human AMH calibrators (r2=0.99, P<0.0001) ensure accuracy and reproducibility assay–to–assay and lot–to–lot Unique mAbs developed against specific linear epitopes Specific on the associated dimers of AMH specificity and consistency of AMH detection, no Specific to the full detectable cross-reactivity to other isoforms of AMH, length and cleaved complex forms of different conformations of AMH, or other TGF-ß AMH superfamily hormones; no interference by complement or heterophilic antibodies Sample size is not the limitation of the assay optimized for dilution in the well; assay can be performed with as little as 10 μL sample size for higher concentrations of AMH, or up to 50 μL of sample when sensitivity down to ~2 pg/mL is required Pepinski, R.B., et al. (1988) J. Biol. Chem., 263, 18961–18964. picoAMH is a useful research tool in Reproductive Endocrinology studies related to: Reliable • Primary ovarian insufficiency In accordance Expected Observed • Oncofertility with NCCLS EP- 1000 • Gonadotoxicity 6-P standards, serum samples • Menopause were diluted 994%4% g/mL and analyzed. 94% • Premature ovarian aging Linearity of 100 ation p 99%99% results was seen tr regardless of 97%97% oncen dilution—from C Neat to 1:320. 10 1:1 1:2 1:4 1:8 1:16 Dilution * Within the U.S., intended for Research Use Only (RUO). Not for use in diagnostic or therapeutic procedures. www.AnshLabs.com 5 Product Focus - Animal Specific AMH Assays Ansh Labs Advantage: Rat and Mouse The animal AMH kits utilize monoclonal antibodies carefully selected for high affinity and specificity for certain species. Where available, species–specific AMH calibrators have been employed. The assays have been optimized to not cross react with other related members of the TGF–β superfamily. The enhanced specificity and analytical sensitivity allow for greater detection of AMH at low concentrations. Applications: Canine • Estimate fertility potential – embryo transfer, Female Canine Male Canine donor recipient 700 14000 • Detect cryptorchidism 600 12000 • Detect granulosa cell tumors 500 10000 400 8000 • Check spay and neuter procedures for 300 6000 remnant tissue pg/mL 200 4000 Species Specific AMH Assays: 100 2000 0 Spay Intact 0 Castrated Intact • Bovine AMH, AL-115 • Canine AMH, AL-116 Bovine • Caprine AMH, AL-154 • Equine AMH, AL-115 • Ovine AMH, AL-155 • Porcine AMH, AL-169 • Primate AMH, AL-105 • Rat / Mouse AMH, AL-113 ng/mL Bovine Breeds Tested • Bos taurus: Jersey, Hereford, Holstein, Angus, Red Angus, Black Angus • Bubalus bubalis: Murrah • Bos indicus: Brahman, Gyr, Nelore • Mixed: Beefmaster, Brangus, Holstein-Jersey, Braford, Bonsmara, Wagyu * Within the U.S., intended for Research Use Only (RUO).
Load more

Recommended publications
  • An Autocrine Activinb Mechanism Drives TGF /Activin Signaling In
    An autocrine ActivinB mechanism drives TGF β/Activin signaling in Group 3 medulloblastoma Morgane Morabito, Magalie Larcher, Florence M G Cavalli, Chloé Foray, Antoine Forget, Liliana Mirabal-ortega, Mamy Andrianteranagna, Sabine Druillennec, Alexandra Garancher, Julien Masliah-planchon, et al. To cite this version: Morgane Morabito, Magalie Larcher, Florence M G Cavalli, Chloé Foray, Antoine Forget, et al.. An autocrine ActivinB mechanism drives TGF β/Activin signaling in Group 3 medulloblastoma. EMBO Molecular Medicine, Wiley Open Access, 2019, 6, pp.e9830. 10.15252/emmm.201809830. hal-02347105 HAL Id: hal-02347105 https://hal.archives-ouvertes.fr/hal-02347105 Submitted on 5 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Article An autocrine ActivinB mechanism drives TGFb/ Activin signaling in Group 3 medulloblastoma Morgane Morabito1,2,3,4,5, Magalie Larcher1,2,3,4,5, Florence MG Cavalli6,7, Chloé Foray1,2,3,4,5, Antoine Forget1,2,3,4,5, Liliana Mirabal-Ortega1,2,3,4,5, Mamy Andrianteranagna5,8,9,10,11,12,13, Sabine Druillennec1,2,3,4,5,
    [Show full text]
  • A Meta-Analysis of the Inhibin Network Reveals Prognostic Value in Multiple Solid Tumors
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.25.171942; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 A meta-analysis of the inhibin network reveals prognostic value in multiple solid tumors Eduardo Listik1†, Ben Horst1,2†, Alex Seok Choi1, Nam. Y. Lee3, Balázs Győrffy4 and Karthikeyan Mythreye1 Affiliations: 1Department of Pathology, University of Alabama at Birmingham, Birmingham AL, USA, 35294. 2Department of Chemistry and Biochemistry, University of South Carolina, Columbia SC, USA, 29208. 3 Division of Pharmacology, Chemistry and Biochemistry, College of Medicine, University of Arizona, Tucson, AZ, 85721, USA. 4 TTK Cancer Biomarker Research Group, Institute of Enzymology, and Semmelweis University Department of Bioinformatics and 2nd Department of Pediatrics, Budapest, Hungary. Corresponding author: Karthikeyan Mythreye, Ph.D. Division of Molecular and Cellular Pathology, Department of Pathology, The University of Alabama at Birmingham. WTI 320B, 1824 Sixth Avenue South, Birmingham, AL, USA, 35294. Phone : +1 205.934.2746 E-mail : [email protected] †The authors contributed equally to this work. bioRxiv preprint doi: https://doi.org/10.1101/2020.06.25.171942; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • Table SI. Characteristics of 9 Patients Chosen from 60 Patients with Hepatocellular Carcinoma
    Table SI. Characteristics of 9 patients chosen from 60 patients with hepatocellular carcinoma. Characteristic No. of patients (%) Age, years <50 3 (33.3) ≥50 6 (66.7) Sex Female 4 (44.4) Male 5 (55.6) Albumin, g/l ≥35 8 (88.9) <35 1 (11.1) AFP, ng/ml ≤20 2 (22.2) >20 7 (77.8) Tumor diameter, cm ≤5 3 (33.3) >5 6 (66.7) Portal vein invasion Without 3 (33.3) With 6 (66.7) BCLC stage A 2 (22.2) B/C 7 (77.8) AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer. Table SII. List of the gene symbol and relative expression of six significant clusters. Gene symbol SPOT Profile Day 0 Day 3 Day 7 Day 14 Day 21 ALCAM ID_10 16 0 -356.5 378.5 0.1 307.8 ANGPT2 ID_13 16 0 -45.7 197.2 96 60.2 CD80 ID_24 16 0 -177 362 -29 187 CTNNB1 ID_29 16 0 -58 294 83 49 BMP4 ID_37 16 0 -107 189 0 53 CCL28 ID_49 16 0 -307 856 491 347 CCR1 ID_50 16 0 -189 391 236 112 CCR4 ID_53 16 0 -101 361 89 240 CCR7 ID_56 16 0 -98 361 103 66 CLC ID_70 16 0 -147 274 0 188 CRIM1 ID_74 16 0 -642 229 -48 -112 CXCL14 ID_83 16 0 -434 1,154.00 778 376 CXCL16 ID_84 16 0 -128 800 477 180 DKK3 ID_97 16 0 -199 610 107 3 FGFBP1 ID_129 16 0 -224 484 -155 37 FGF20 ID_147 16 0 -113 264 -32 -4 WFIKKN1 ID_163 16 0 -195 544 262 41 GFRA1 ID_175 16 0 -536 443 29 280 GFRA4 ID_178 16 0 -211 208 -47 116 TNFSF18 ID_180 16 0 -14 246 89 68 GPC5 ID_187 16 0 -180 1,345.00 298 509 GH1 ID_194 16 0 -596 206 10 -9 CCHCR1 ID_198 16 0 -108 322 50 238 NRG1 ID_200 16 0 -81 378.5 170.5 187 ICAM1 ID_207 16 0 -136 98 -17 63 IFNB1 ID_213 16 0 -87 233 143 29 IGFBP3 ID_218 16 0 -1,311.00 609 -368 -178 IGFBP4 ID_219 16 0
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • The Expression of Genes Contributing to Pancreatic Adenocarcinoma Progression Is Influenced by the Respective Environment – Sagini Et Al
    The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment – Sagini et al Supplementary Figure 1: Target genes regulated by TGM2. Figure represents 24 genes regulated by TGM2, which were obtained from Ingenuity Pathway Analysis. As indicated, 9 genes (marked red) are down-regulated by TGM2. On the contrary, 15 genes (marked red) are up-regulated by TGM2. Supplementary Table 1: Functional annotations of genes from Suit2-007 cells growing in pancreatic environment Categoriesa Diseases or p-Valuec Predicted Activation Number of genesf Functions activationd Z-scoree Annotationb Cell movement Cell movement 1,56E-11 increased 2,199 LAMB3, CEACAM6, CCL20, AGR2, MUC1, CXCL1, LAMA3, LCN2, COL17A1, CXCL8, AIF1, MMP7, CEMIP, JUP, SOD2, S100A4, PDGFA, NDRG1, SGK1, IGFBP3, DDR1, IL1A, CDKN1A, NREP, SEMA3E SERPINA3, SDC4, ALPP, CX3CL1, NFKBIA, ANXA3, CDH1, CDCP1, CRYAB, TUBB2B, FOXQ1, SLPI, F3, GRINA, ITGA2, ARPIN/C15orf38- AP3S2, SPTLC1, IL10, TSC22D3, LAMC2, TCAF1, CDH3, MX1, LEP, ZC3H12A, PMP22, IL32, FAM83H, EFNA1, PATJ, CEBPB, SERPINA5, PTK6, EPHB6, JUND, TNFSF14, ERBB3, TNFRSF25, FCAR, CXCL16, HLA-A, CEACAM1, FAT1, AHR, CSF2RA, CLDN7, MAPK13, FERMT1, TCAF2, MST1R, CD99, PTP4A2, PHLDA1, DEFB1, RHOB, TNFSF15, CD44, CSF2, SERPINB5, TGM2, SRC, ITGA6, TNC, HNRNPA2B1, RHOD, SKI, KISS1, TACSTD2, GNAI2, CXCL2, NFKB2, TAGLN2, TNF, CD74, PTPRK, STAT3, ARHGAP21, VEGFA, MYH9, SAA1, F11R, PDCD4, IQGAP1, DCN, MAPK8IP3, STC1, ADAM15, LTBP2, HOOK1, CST3, EPHA1, TIMP2, LPAR2, CORO1A, CLDN3, MYO1C,
    [Show full text]
  • The TGF-Β Family in the Reproductive Tract
    Downloaded from http://cshperspectives.cshlp.org/ on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press The TGF-b Family in the Reproductive Tract Diana Monsivais,1,2 Martin M. Matzuk,1,2,3,4,5 and Stephanie A. Pangas1,2,3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030 2Center for Drug Discovery, Baylor College of Medicine, Houston, Texas 77030 3Department of Molecular and Cellular Biology, Baylor College of Medicine Houston, Texas 77030 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030 5Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030 Correspondence: [email protected]; [email protected] The transforming growth factor b (TGF-b) family has a profound impact on the reproductive function of various organisms. In this review, we discuss how highly conserved members of the TGF-b family influence the reproductive function across several species. We briefly discuss how TGF-b-related proteins balance germ-cell proliferation and differentiation as well as dauer entry and exit in Caenorhabditis elegans. In Drosophila melanogaster, TGF-b- related proteins maintain germ stem-cell identity and eggshell patterning. We then provide an in-depth analysis of landmark studies performed using transgenic mouse models and discuss how these data have uncovered basic developmental aspects of male and female reproductive development. In particular, we discuss the roles of the various TGF-b family ligands and receptors in primordial germ-cell development, sexual differentiation, and gonadal cell development. We also discuss how mutant mouse studies showed the contri- bution of TGF-b family signaling to embryonic and postnatal testis and ovarian development.
    [Show full text]
  • Activin/Nodal Signalling in Stem Cells Siim Pauklin and Ludovic Vallier*
    © 2015. Published by The Company of Biologists Ltd | Development (2015) 142, 607-619 doi:10.1242/dev.091769 REVIEW Activin/Nodal signalling in stem cells Siim Pauklin and Ludovic Vallier* ABSTRACT organisms. Of particular relevance, genetic studies in the mouse Activin/Nodal growth factors control a broad range of biological have established that Nodal signalling is necessary at the early processes, including early cell fate decisions, organogenesis and epiblast stage during implantation, in which the pathway functions adult tissue homeostasis. Here, we provide an overview of the to maintain the expression of key pluripotency factors as well as to mechanisms by which the Activin/Nodal signalling pathway governs regulate the differentiation of extra-embryonic tissue. Activins, β stem cell function in these different stages of development. dimers of different subtypes of Inhibin , are also expressed in pre- We describe recent findings that associate Activin/Nodal signalling implantation blastocyst but not in the primitive streak (Albano to pathological conditions, focusing on cancer stem cells in et al., 1993; Feijen et al., 1994). However, genetic studies have β tumorigenesis and its potential as a target for therapies. Moreover, shown that Inhibin s are not necessary for early development in the we will discuss future directions and questions that currently remain mouse (Lau et al., 2000; Matzuk, 1995; Matzuk et al., 1995a,b). unanswered on the role of Activin/Nodal signalling in stem cell self- Combined gradients of Nodal and BMP signalling within the renewal, differentiation and proliferation. primitive streak control endoderm and mesoderm germ layer specification and also their subsequent patterning whilst blocking KEY WORDS: Activin, Cell cycle, Differentiation, Nodal, neuroectoderm formation (Camus et al., 2006; Mesnard et al., Pluripotency, Stem cells 2006).
    [Show full text]
  • Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells in Vitro Dulama Richani
    1 Cumulin and FSH cooperate to regulate inhibin B and activin B production by human 2 granulosa-lutein cells in vitro 3 4 Dulama Richani*1, Katherine Constance1, Shelly Lien1, David Agapiou1, William A. 5 Stocker2,3, Mark P. Hedger4, William L. Ledger1, Jeremy G. Thompson5, David M. 6 Robertson1, David G. Mottershead5,6, Kelly L. Walton2, Craig A. Harrison2 and Robert B. 7 Gilchrist1 8 9 1 Fertility and Research Centre, School of Women’s and Children’s Health, University of 10 New South Wales Sydney, Australia 11 2 Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, 12 Clayton, Australia 13 3 Department of Chemistry and Biotechnology, Swinburne University of Technology, 14 Hawthorn, Victoria 3122, Australia 15 4 Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, VIC, 16 Australia 17 5 Robinson Research Institute, Adelaide Medical School, The University of Adelaide, 18 Australia 19 6 Institute for Science and Technology in Medicine, School of Pharmacy, Keele University, 20 Newcastle-under-Lyme, UK 21 22 Short Title: Cumulin and FSH jointly regulate inhibin/activin B 23 24 Corresponding author: 25 *Dulama Richani ([email protected]) 1 26 Wallace Wurth Building, UNSW Sydney, Kensington, NSW 2052, Australia 27 28 Re-print requests: 29 Dulama Richani ([email protected]) 30 Wallace Wurth Building, UNSW Sydney, Kensington, NSW 2052, Australia 31 32 Key words: 33 GDF9, BMP15, cumulin, FSH, inhibin, activin 34 35 Funding: 36 The work was funded by National Health and Medical Research Council of Australia grants 37 (APP1017484, APP1024358, APP1121504 awarded to DGM, CAH, and RBG, respectively) 38 and fellowships (APP1023210, APP1117538 awarded to RBG), and by Strategic Funds from 39 the University of New South Wales Sydney awarded to RBG.
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis
    Author Manuscript Published OnlineFirst on March 13, 2018; DOI: 10.1158/0008-5472.CAN-17-2316 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Inhibin is a novel paracrine factor for tumor angiogenesis and metastasis Priyanka Singh1#, Laura M. Jenkins1#, Ben Horst1, Victoria Alers1, Shrikant Pradhan1, Prabhjot Kaur2, Tapasya Srivastava2, Nadine Hempel3, Balázs Győrffy4, Eugenia V. Broude5, Nam Y. Lee6, and Karthikeyan Mythreye5,1,* 1Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, USA 2Department of Genetics, University of Delhi, South Campus, India. 3Department of Pharmacology, Penn State University College of Medicine, Hershey PA 4MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology; Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary. 5Department of Drug Discovery and Biomedical Sciences, School of Pharmacy, 6 Division of Pharmacology, College of Pharmacy, Ohio State University, Columbus, Ohio, USA # Equal contribution Running title: Inhibin promotes angiogenesis and metastasis * Correspondence to K. Mythreye: [email protected] Mailing address: Department of Chemistry and Biochemistry University of South Carolina, 631 Sumter Street Columbia SC 29208 Tel: (803) 576-5806, Fax: (803) 777-9521 Authors declare no conflict of interest. Keywords: Inhibin, Endoglin, ALK1, Angiogenesis, Ovarian cancer, Paracrine 1 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 13, 2018; DOI: 10.1158/0008-5472.CAN-17-2316 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Inhibin is a heterodimeric TGF-β family ligand that is expressed in many cancers and is a selective biomarker for ovarian cancers, however its tumor-specific functions remain unknown.
    [Show full text]
  • Context-Dependent Roles in Cell and Tissue Physiology
    Downloaded from http://cshperspectives.cshlp.org/ on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press TGF-b and the TGF-b Family: Context-Dependent Roles in Cell and Tissue Physiology Masato Morikawa,1 Rik Derynck,2 and Kohei Miyazono3 1Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, Biomedical Center, SE-751 24 Uppsala, Sweden 2Department of Cell and Tissue Biology, University of California at San Francisco, San Francisco, California 94143 3Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan Correspondence: [email protected] The transforming growth factor-b (TGF-b) is the prototype of the TGF-b family of growth and differentiation factors, which is encoded by 33 genes in mammals and comprises homo- and heterodimers. This review introduces the reader to the TGF-b family with its complexity of names and biological activities. It also introduces TGF-b as the best-studied factor among the TGF-b family proteins, with its diversity of roles in the control of cell proliferation and differentiation, wound healing and immune system, and its key roles in pathology, for exam- ple, skeletal diseases, fibrosis, and cancer. lthough initially thought to stimulate cell TGF-b has been well documented in most cell Aproliferation, just like many growth factors, types, and has been best characterized in epithe- it became rapidly accepted that transforming lial cells. The bifunctional and context-depen- growth factor b (TGF-b) is a bifunctional reg- dent nature of TGF-b activities was further con- ulator that either inhibits or stimulates cell pro- firmed in a large variety of cell systems and liferation.
    [Show full text]
  • Primary Chicken and Duck Endothelial Cells Display a Differential Response to Infection with Highly Pathogenic Avian Influenza Virus
    G C A T T A C G G C A T genes Article Primary Chicken and Duck Endothelial Cells Display a Differential Response to Infection with Highly Pathogenic Avian Influenza Virus Zhen Wei Marcus Tong 1,†, Anjana C. Karawita 1,2,† , Colin Kern 3, Huaijun Zhou 3 , Jane E. Sinclair 1 , Limin Yan 1, Keng Yih Chew 1, Sue Lowther 2, Lee Trinidad 2, Arjun Challagulla 2 , Karel A. Schat 4 , Michelle L. Baker 2 and Kirsty R. Short 1,5,* 1 School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia; [email protected] (Z.W.M.T.); [email protected] (A.C.K.); [email protected] (J.E.S.); [email protected] (L.Y.); [email protected] (K.Y.C.) 2 CSIRO, Australian Centre for Disease Preparedness, Health, and Biosecurity Business Unit, Geelong 3219, Australia; [email protected] (S.L.); [email protected] (L.T.); [email protected] (A.C.); [email protected] (M.L.B.) 3 Department of Animal Science, University of California, Davis, CA 95616, USA; [email protected] (C.K.); [email protected] (H.Z.) 4 Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA; [email protected] 5 Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane 4072, Australia * Correspondence: [email protected] † These authors contributed equally to this work. Citation: Tong, Z.W.M.; Karawita, A.C.; Kern, C.; Zhou, H.; Sinclair, J.E.; Abstract: Highly pathogenic avian influenza viruses (HPAIVs) in gallinaceous poultry are associated Yan, L.; Chew, K.Y.; Lowther, S.; Trinidad, L.; Challagulla, A.; et al.
    [Show full text]